<?xml version="1.0"?>
<rss version="2.0">
  <channel>
    <title>RxPG News : Hypnotics</title>
      <link>http://www.rxpgnews.com/</link>
      <description>Medical News and Information</description>
      <pubDate>Thu, 21 Aug 2008 02:00:28 PST</pubDate>
      <language>en-us</language>
      <item>
        <title>Ramelteon shows less potential to foster abuse and dependence</title>
        <link>http://www.rxpgnews.com/ramelteon/Ramelteon_shows_less_potential_to_foster_abuse_and_4370_4370.shtml</link>
        <category>Ramelteon</category>
        <description>As part of the effort to develop effective behavioral and medical sleep therapies, scientists consider the potential for dependence and abuse associated with prescription sleep drugs. This line of research has produced findings showing that a recently approved prescription sleep drug may spare users the potential for dependence and abuse found with other sleep aids. Laboratory studies of the effects of ramelteon suggest that the drug&#39;s targeting of the brain&#39;s melatonin receptors rather than its benzodiazepine receptors make its subjective side effects different from those of old and new sedative hypnotics. </description>
        <pubDate>Mon, 05 Jun 2006 16:19:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/ramelteon/Ramelteon_shows_less_potential_to_foster_abuse_and_4370_4370.shtml</guid>
      </item>
      <item>
        <title>Ramelteon showed significant reduction in time to fall asleep</title>
        <link>http://www.rxpgnews.com/ramelteon/Ramelteon_showed_significant_reduction_in_time_to__3898_3898.shtml</link>
        <category>Ramelteon</category>
        <description>Results of a sub-analysis from a Phase III clinical study showed that ROZEREMTM (ramelteon) significantly reduced time to fall asleep in adults with chronic insomnia and showed no evidence of rebound insomnia or withdrawal effects. The results were presented today at the 2006 Annual Meeting of the American Academy of Neurology.</description>
        <pubDate>Mon, 03 Apr 2006 23:35:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/ramelteon/Ramelteon_showed_significant_reduction_in_time_to__3898_3898.shtml</guid>
      </item>
      <item>
        <title>CX717 Reverses Effects of Sleep Deprivation on Brain</title>
        <link>http://www.rxpgnews.com/hypnotics/CX717_Reverses_Effects_of_Sleep_Deprivation_on_Bra_2140_2140.shtml</link>
        <category>Hypnotics</category>
        <description>Research in monkeys suggests that a new drug can temporarily improve performance and reverse the effects of sleep deprivation on the brain, which would be a breakthrough in helping shift workers, health professionals, military personnel and others who must function at top performance in spite of sleep deficits.</description>
        <pubDate>Wed, 24 Aug 2005 04:15:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/hypnotics/CX717_Reverses_Effects_of_Sleep_Deprivation_on_Bra_2140_2140.shtml</guid>
      </item>
      <item>
        <title>Approval for Clonazepam Orally Disintegrating Tablets</title>
        <link>http://www.rxpgnews.com/hypnotics/Approval_for_Clonazepam_Orally_Disintegrating_Tabl_2045_2045.shtml</link>
        <category>Hypnotics</category>
        <description>Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market Clonazepam Orally Disintegrating Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg &amp;amp; 2 mg, the generic equivalent of Hoffman La Roche&#39;s Klonopin(R) Wafers. The Company plans to launch its product immediately. </description>
        <pubDate>Thu, 11 Aug 2005 22:58:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/hypnotics/Approval_for_Clonazepam_Orally_Disintegrating_Tabl_2045_2045.shtml</guid>
      </item>
      <item>
        <title>NDA accepted to review Indiplon for the treatment of insomnia</title>
        <link>http://www.rxpgnews.com/hypnotics/NDA_accepted_to_review_Indiplon_for_the_treatment__1935_1935.shtml</link>
        <category>Hypnotics</category>
        <description>Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company&#39;s New Drug Application (NDA) for indiplon tablets for review for the treatment of insomnia in both adult and elderly patients. </description>
        <pubDate>Wed, 27 Jul 2005 13:44:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/hypnotics/NDA_accepted_to_review_Indiplon_for_the_treatment__1935_1935.shtml</guid>
      </item>
      <item>
        <title>FDA Approves Ramelteon, the First &#39;No Abuse&#39; Drug for Insomnia</title>
        <link>http://www.rxpgnews.com/ramelteon/FDA_Approves_Ramelteon_the_First_No_Abuse_Drug_for_1914_1914.shtml</link>
        <category>Ramelteon</category>
        <description>Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREM(TM) (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ROZEREM for long-term use in adults. </description>
        <pubDate>Sat, 23 Jul 2005 23:56:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/ramelteon/FDA_Approves_Ramelteon_the_First_No_Abuse_Drug_for_1914_1914.shtml</guid>
      </item>
      <item>
        <title>FDA approved Ramelteon</title>
        <link>http://www.rxpgnews.com/ramelteon/FDA_approved_Ramelteon_1911_1911.shtml</link>
        <category>Ramelteon</category>
        <description>Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREMTM (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ROZEREM for long-term use in adults.</description>
        <pubDate>Sat, 23 Jul 2005 18:12:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/ramelteon/FDA_approved_Ramelteon_1911_1911.shtml</guid>
      </item>
      <item>
        <title>Older adults falling asleep faster with Ramelteon</title>
        <link>http://www.rxpgnews.com/hypnotics/Older_adults_falling_asleep_faster_with_Ramelteon_1453_1453.shtml</link>
        <category>Hypnotics</category>
        <description>Results from a Phase 3 clinical study presented at the 2005 Annual Scientific Meeting of the American Geriatrics Society showed that bedtime administration of ramelteon, an investigational compound currently under review for the treatment of insomnia, significantly reduced time to fall asleep in older adults with chronic insomnia. Additionally, no rebound insomnia or withdrawal effects were observed.</description>
        <pubDate>Fri, 13 May 2005 16:54:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/hypnotics/Older_adults_falling_asleep_faster_with_Ramelteon_1453_1453.shtml</guid>
      </item>


  </channel>
</rss>
